Update: CVS stock drops 11% after announcing its breakup, wiping out about $13.5 billion

This updates our morning report on CVS Health's plan to split into two public companies by the first half of 2028. At that point the stock was indicated down about 3% before the open. By 3:26 PM ET, Nasdaq showed CVS at $80.98, down $10.43 or 11.41% from Tuesday's $91.41 close, despite a third-quarter beat and a raised 2026 profit forecast announced the same morning.

The numbers behind the drop

Measure (Nasdaq, 3:26 PM ET)	Value
Last price	$80.98
Change from Tuesday's close	-$10.43 (-11.41%)
Today's range	$77.33 to $85.05
Volume	about 27.3 million shares, 3.6 times the 7.6 million average
Market value	about $103.5 billion, against $117 billion cited by CNBC
52-week range	$69.51 to $110.68

The stock has traded between $77.33 and $85.05 today. The market value gap is simple arithmetic: $117 billion at the pre-announcement price versus about $103.5 billion now, roughly $13.5 billion lower. Figures are intraday and will change by the close.

Why the market is not cheering

CNBC reported that CEO David Joyner told analysts the split comes “out of strength,” and that the company has beaten earnings estimates for eight straight quarters. The reaction suggests investors are focused on what is being given up. Two points came up in analyst notes CNBC quoted:

• The pharmacy-to-PBM pipeline. Caremark steers members to CVS stores through programs such as Maintenance Choice, which sends volume to retail. Today the profit from that stays inside one company. Leerink's Michael Cherny wrote that the question is whether future contracts “preserve the same competitive advantages and flexibility” as common ownership. Joyner said the synergies will be kept in commercial agreements between the two companies, which CVS will work on over the next 15 to 18 months.
• Medicare Advantage ratings. RBC's Ben Hendrix raised the question of how a separation affects Aetna's star ratings, which decide eligibility for government bonus payments. Retail pharmacists help engage Aetna members, and a split could complicate that.

The retail half is also a thin-margin business. CNBC put adjusted operating margins at roughly 4% to 5%. Jefferies' Brian Tanquilut cautioned that some recent store gains came because Walgreens and others closed locations, which may not repeat.

What most coverage gets wrong

The obvious read is that the market is punishing a company for doing something sensible. The more precise read is that it is repricing a package. For two years CVS's pitch was that insurer, benefit manager and pharmacy were worth more together. Splitting them concedes that the combination was not being rewarded, and it puts the connecting contracts, not the businesses, at the center of the next 18 months. The company has not said what those contracts will look like, and neither the 8-K nor the release gives terms.

Who this reaches

• Independent pharmacy owners compete with CVS stores and also depend on Caremark's network rules. A standalone CVS Pharmacy and a separate Caremark could treat outside pharmacies differently. Nothing in the filings says how, so owners should read the Form 10 when it arrives rather than guess.
• Employers that buy Aetna coverage with Caremark drug benefits keep that pairing, since both stay in one company.
• Shareholders will own stock in both companies, according to CNBC, and the stock's move today is the market's first price on that bundle.

What to watch

The Form 10 registration statement, which will show each company's separate financials, and any early detail on the commercial agreements. State laws in Tennessee and Arkansas that ban common ownership of a PBM and a pharmacy are under court challenge, according to CNBC; Joyner told the Wall Street Journal regulation was not the reason for the split, though Cherny said he was unsure.

Sources: CNBC and CNBC analysis, Nov. 4, 2026; CVS Health filings on SEC EDGAR; Nasdaq quote data read at 3:26 PM ET; Yahoo Finance price history. Quotes are intraday and can change. This is market information, not investment advice.